- Home
- EVF vs ABOS Comparison
EVF vs ABOS Comparison
Compare EVF & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVF
- ABOS
- Stock Information
- Founded
- EVF 1998
- ABOS 1996
- Country
- EVF United States
- ABOS United States
- Employees
- EVF N/A
- ABOS N/A
- Industry
- EVF Investment Managers
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- EVF Finance
- ABOS Health Care
- Exchange
- EVF Nasdaq
- ABOS Nasdaq
- Market Cap
- EVF 101.0M
- ABOS 84.2M
- IPO Year
- EVF N/A
- ABOS 2021
- Fundamental
- Price
- EVF $5.54
- ABOS $1.23
- Analyst Decision
- EVF
- ABOS Strong Buy
- Analyst Count
- EVF 0
- ABOS 3
- Target Price
- EVF N/A
- ABOS $8.00
- AVG Volume (30 Days)
- EVF 93.3K
- ABOS 188.0K
- Earning Date
- EVF 01-01-0001
- ABOS 11-11-2025
- Dividend Yield
- EVF 10.68%
- ABOS N/A
- EPS Growth
- EVF N/A
- ABOS N/A
- EPS
- EVF 0.94
- ABOS N/A
- Revenue
- EVF N/A
- ABOS N/A
- Revenue This Year
- EVF N/A
- ABOS N/A
- Revenue Next Year
- EVF N/A
- ABOS N/A
- P/E Ratio
- EVF $6.74
- ABOS N/A
- Revenue Growth
- EVF N/A
- ABOS N/A
- 52 Week Low
- EVF $5.20
- ABOS $0.86
- 52 Week High
- EVF $6.84
- ABOS $3.36
- Technical
- Relative Strength Index (RSI)
- EVF 46.38
- ABOS 39.55
- Support Level
- EVF $5.48
- ABOS $1.34
- Resistance Level
- EVF $5.60
- ABOS $1.47
- Average True Range (ATR)
- EVF 0.04
- ABOS 0.08
- MACD
- EVF 0.00
- ABOS -0.02
- Stochastic Oscillator
- EVF 50.00
- ABOS 7.69
About EVF Eaton Vance Senior Income Trust
Eaton Vance Senior Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide a high level of current income consistent with the preservation of capital, by investing in senior, secured floating-rate loans. The trust invests in below-investment-grade floating-rate loans, which are considered speculative because of the credit risk of their issuers. Its portfolio of investment consists of aerospace and defense, automotive, beverage, building and development, business equipment and services, cable and satellite television, and other areas.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.